Bioresorbable Vascular Scaffolds in a Real-World Patient Population-Results From a Mid-Term Angiographic Follow-Up

Journal of Interventional Cardiology

Volumn 29, Issue 4, 2016, Pages 341-347

  Saad, Mohammed ^a,b,c,d   Abdin, Amr ^b,c,d   Thiele, Holger ^c,d   Desch, Steffen ^c,d   Ibrahimi, Pranvera ^a   Wikstroem, Gerhard ^e   Hoeher, Martin ^b   Henein, Michael ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b INSTITUTE OF PATHOLOGY   (Germany)

^c University Heart Center Lübeck   (Germany)

^d DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; CAUSE OF DEATH; CLINICAL FEATURE; CORONARY ANGIOGRAPHY; CORONARY ARTERY OCCLUSION; CORONARY ARTERY RECANALIZATION; CORONARY STENTING; DEVICE SAFETY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; RESTENOSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

EID: 84979941545     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/joic.12297     Document Type: Article

References (26)

1. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. Lancet 2012; 379:1393–1402.
2. Stefanini GG, Holmes DR, Jr. Drug-eluting coronary-artery stents. N Engl J Med 2013; 368:254–265.
3. Garg S, Serruys PW. Coronary stents: Current status. J Am Coll Cardiol 2010; 56:S1–42.
4. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neo-atherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57:1314–1322.
5. Iqbal J, Onuma Y, Ormiston J, et al. Bioresorbable scaffolds: Rationale, current status, challenges, and future. Eur Heart J Mar 2014; 35:765–776.
6. Wykrzykowska JJ, Onuma Y, Serruys PW. Vascular restoration therapy: The fourth revolution in interventional cardiology and the ultimate “rosy” prophecy. EuroIntervention 2009;(5 Suppl. F):F7–F8.
7. Garcia-Garcia HM, Serruys PW, Campos CM, et al. Assessing bioresorbable coronary devices: Methods and parameters. JACC Cardiovasc Imaging 2014; 7:1130–1148.
8. Wykrzykowska JJ, Onuma Y, Serruys PW. Advances in stent drug delivery: The future is in bioabsorbable stents. Expert Opin Drug Deliv 2009; 6:113–126.
9. Serruys PW, Onuma Y, Ormiston JA, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: Six-month clinical and imaging outcomes. Circulation 2010; 122:2301–2312.
10. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011; 58:1578–1588.
11. Onuma Y, Serruys PW, Gomez J, et al. ABSORB Cohort A and B investigators. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv 2011; 78:3–12.
12. Muramatsu T, Onuma Y, vanGeuns RJ, et al. ABSORB Cohort B Investigators; ABSORB EXTEND Investigators; SPIRIT FIRST Investigators; SPIRIT II Investigators; SPIRIT III Investigators; SPIRIT IV Investigators. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: A pooled analysis of the ABSORB and the SPIRIT trials. JACC Cardiovasc Interv 2014; 7:482–493.
13. Gori T, Schulz E, Hink U, et al. Early outcome after implantation of absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention 2014; 9:1036–1041.
14. Kocka V, Maly M, Tousek P, et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: A prospective multi-center study ‘Prague 19’. Eur Heart J 2014; 35:787–794.
15. Diletti R, Karanasos A, Muramatsu T, et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J 2014; 35:777–786.
16. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115(17):2344–2351.
17. Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: Early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015; 10:1144–1153.
18. Kraak RP, Hassell ME, Grundeken MJ, et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: The AMC Single Centre Real World PCI Registry. EuroIntervention 2015; 10:1160–1168.
19. Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011; 123:1400–1409.
20. Costopoulos C, Latib A, Naganuma T, et al. Comparison of early clinical outcomes between absorb bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Catheter Cardiovasc Interv 2015; 85:E10–E15.
21. Cortese B, Ielasi A, Romagnoli E, et al. Clinical comparison with short-term follow-up of bioresorbable vascular scaffold versus everolimus-eluting stent in primary percutaneous coronary interventions. Am J Cardiol 2015; 116(5):705–710.
22. Brugaletta S, Gori T, Low AF, et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: The BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv 2015; 8(1 Pt B):189–197.
23. De Ribamar Costa J, Jr., Abizaid A, Bartorelli AL, et al. Impact of post-dilation on the acute and one-year clinical outcomes of a large cohort of patients treated solely with the absorb bioresorbable vascular scaffold. EuroIntervention 2015; 11(2):141–148.
24. Abizaid A, Ribamar Costa J, Jr., Bartorelli AL, et al. The ABSORB EXTEND study: Preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention 2015; 10(12):1396–1401.
25. Wöhrle J, Naber C, Schmitz T, et al. Beyond the early stages: Insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention 2014.
26. Costopoulos C, Latib A, Naganuma T, et al. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Catheter Cardiovasc Interv 2015; 85(1):E10–5.